# Adversarial re-verification — osteofibrous_dysplasia.md (wave7)

1. DOSE LEAK: none. No mg, mg/m2, AUC, cycle count, or numbered schedule anywhere in the file. All content is qualitative (observation, bracing, curettage/resection with grafting, surveillance).

2. UNGROUNDED / MISLABELLED CLAIMS: none found. Re-verified independently against devita.txt:
   - `grep -i "osteofibrous"` → 1 hit total, the bibliography citation only (line 222999, "Most MJ, Sim FH, Inwards CY. Osteofibrous dysplasia and adamantinoma").
   - `grep -i "adamantinoma"` → hits are: (a) line 220287, one sentence "Adamantinoma is most frequently encountered in the tibia and/or fibula" (anatomic list, cited to the same Most/Sim/Inwards ref 43, no treatment detail); (b) lines 220424-220425, bare entries "Adamantinoma of long bones" / "Dedifferentiated adamantinoma" inside a WHO histologic-classification table, no surrounding management text; (c) the bibliography citation; (d) unrelated "adamantinomatous" hits re: craniopharyngioma (~line 242799-242806).
   - No management, regimen, drug, or trial content for OFD or adamantinoma exists anywhere in the supplied DeVita text — confirms there is nothing to fabricate a mis-attribution from.
   - Every clinical claim in the body (observation-first posture, bracing, deferred surgery/curettage+grafting/osteotomy, biopsy for epithelial component, cytokeratin IHC, adamantinoma-spectrum reclassification, no role for radiotherapy/systemic therapy) carries the inline tag `(general oncology standard, not from DeVita's section on this disease)`. No specific trial name, drug, or numeric statistic is asserted anywhere.

3. CITATION: fixed. Trailing line now reads: "Sources: DeVita 12th ed. (bibliographic/anatomic mention only; no OFD or adamantinoma management section found). Management content reflects general orthopedic-oncology standard of care; confirm against WHO Classification of Tumours: Soft Tissue and Bone or Enzinger and Weiss." Name only, no page numbers, and no longer implies DeVita as the source of the management content — this resolves the prior blocking mis-attribution issue (the old generic "Sources: DeVita, Hellman, and Rosenberg's..." trailer read alone as a DeVita attribution; the new wording states plainly that DeVita has no such section).

4. VERDICT: CLEAN — ready for R1 re-review. No dose leak, no fabricated/mislabelled content, and the citation line now honestly scopes DeVita's (near-zero) contribution instead of implying it as the source.
